Loading company…
Orchid Biosciences develops genetic testing and reporting tools to assess disease risks in future children and embryos.
Founded in 2019, Orchid Biosciences develops genetic testing and reporting products for prospective parents and people pursuing IVF. Its at-home saliva test assesses genetic risks, while its Embryo Report is intended to help prioritize embryos for transfer. Noor Siddiqui is the CEO. In April 2021, the company raised USD 4.5 million in seed funding from Refactor Capital, Village Global, Day One Ventures, Olive Capital, Boom Capital and others.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in